COMPANY OVERVIEW

A hematology company that is applying new insights in hepcidin biology to develop first-in-class therapies for hematologic diseases.

---

LOCATION

Cambridge, MA, USA

---

THERAPEUTIC AREAS

Hematology

---

WEBSITE

https://www.discmedicine.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Jan 19, 2023

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

Dec 27, 2022

Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

Dec 13, 2022

Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

Nov 3, 2022

Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

Oct 31, 2022

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

For More Press Releases

---